ADC Therapeutics Expands Workforce with New Inducement Grants for Employees

ADC Therapeutics SA (NYSE: ADCT), a leader in the innovative field of antibody-drug conjugates (ADCs), recently made a significant move to bolster its workforce. On August 1, 2025, the company announced that it has allocated a total of 127,000 stock options to three new hires, as part of its new Inducement Plan. This initiative aims not only to attract exceptional talent but also to motivate and reward employees for their contributions to the company's success.

The stock options granted are designed to incentivize new team members to perform at their best and to embed themselves in ADC Therapeutics' vision of advancement in cancer treatment. Each grant is structured to vest over time, with 25% becoming exercisable on the first anniversary of the grant and the remaining options vesting monthly thereafter, culminating in full vesting after four years, contingent on continued employment. This approach is reflective of ADC Therapeutics' commitment to building a dedicated workforce that is aligned with the company’s innovative trajectory.

These inducement grants were approved by the Compensation Committee of ADC Therapeutics' Board of Directors and comply with the NYSE Listed Company Manual's Rule 303A.08, which permits such grants as an inducement for new employees. The plan underscores the company's focus on strategic growth and its focus on incentivizing performance, which is vital for a company operating in the highly competitive biopharmaceutical ecosystem.

ADC Therapeutics and its Mission

Founded in Lausanne, Switzerland, ADC Therapeutics has emerged as a pioneer in the development of antibody-drug conjugates, which transform treatment landscapes for patients. The company’s flagship product, ZYNLONTA (loncastuximab tesirine-lpyl), has received notable approvals from the FDA and the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma. The company has illustrated a clear pathway to advance therapies through its expertise in ADC technology.

As ADC Therapeutics continues to innovate, the company is not only focusing on the existing ADC products like ZYNLONTA but is also investing in the development of next-generation therapeutic options. This includes a novel PSMA-targeting ADC that leverages a unique exatecan-based payload. The integration of advanced technologies and specialized skills to support clinical development, manufacturing, and commercialization is central to ADC Therapeutics's strategy of fostering impactful treatments for patients.

Looking Ahead

While the grants to new employees signal ADC Therapeutics' commitment to growth and performance, the company is also navigating the complexities of the biopharmaceutical industry. With risks ranging from regulatory approvals to the success of clinical trials, ADC Therapeutics is keenly aware of the challenges ahead. The company is focused on ensuring revenue growth, particularly for ZYNLONTA in the U.S. market, and its global partners' efforts to commercialize the product further afield.

The company's forward-looking strategy also encompasses ongoing research initiatives aimed at expanding treatment options for patients, thus fulfilling their mission of transformation in healthcare.

In conclusion, ADC Therapeutics' recent announcements reflect a proactive approach to human resource management, anchored in its mission to innovate within the ADC sector. As the company continues to grow, its ability to harness talent effectively will be crucial to its long-term success and impact on the treatment landscape for patients worldwide.

For more information about ADC Therapeutics, visit adctherapeutics.com.